ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2650

Silent Ischemic Heart Disease In Patients With Primary Antiphospholipid Syndrome

Antonio R. Cabral1, Gregoria Gómez-Hernández2, Martha Morelos-Guzmán3, Tatiana Rodriguez-Reyna4, Carlos Alberto Núñez-Alvarez5 and Jorge Vazquez-Lamadrid3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 2Internal Medicine, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 3Radiology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 4Immunology and Rheumatology, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Premature atherosclerosis in PAPS is still a matter of debate

Patients and Methods:   To determine the prevalence of ischemic heart disease in PAPS patients. Inclusion criteria: Patients ≥18 years of age included in the Patients Registry of the Department of Immunology and Rheumatology from our Institution with the diagnosis of PAPS (Sydney and Alarcón-Segovia et al classifications criteria). All patients gave their written informed consent.  Exclusion criteria: creatinine >1.5 mg/dl, BP persistently >150/90 in spite of treatment, diabetes mellitus (I or II), dyslipidemia, SLE, positive anti-dsDNAcd (ELISA), positive antinucleosome antibodies (ELISA), asthma and/or pregnancy. All patients had a coronary CAT scan both at rest and under stress myocardial perfusión with adenosine (140 µg/kg/min for 3 minutes) with a 64 channel tomograph (G.E Milwaukee, USA). We also determined new aCL (IgG, IgA e IgM), anti-β2GP-I (IgG, IgM e IgA), anti-dsDNA and anti-nucleosomes (all by ELISA). Lipid profile and serum creatinine were also newly determined. Our study was approved by the IRB of our Institution. 

Results: We studied 24 patients (15 women) with PAPS with a mean age of 29 ± 9.8 years at time of study and 9.5 ± 5.5 years of disease duration. None of them had a history of coronary symptoms. We found that 14/24 patients (58%) had abnormal myocardial perfusion under stress with adenosine, 95% of them with normal coronary arteries. No valvular abnormalities were found. Only one patient (4%) had a previous EKG with ischemic abnormalities. The BMI for the whole group was 26.1 ± 4.5 kg/m2 and 54% had history of cigarette consumption (TI= 9.7 ± 3.2). aCL y anti-β2GP-I (any isotype) were positive in 86 and 96% of cases, respectively. We confirmed that no patient had positive anti-DNA, antinucleosomes nor hyperlipidemia. 

Conclusion: We found no direct evidence of epicardial coronary atherosclerosis with aPL in PAPS patients, even after 10 years of follow-up. We also show a high prevalence of abnormal myocardial perfusión (58%) in PAPS patients with normal epicardial coronary arteries. Our study suggests silent myocardial ischemia perhaps due to endothelitis and/or microthrombosis in patients with primary antiphospholipid syndrome.


Disclosure:

A. R. Cabral,
None;

G. Gómez-Hernández,
None;

M. Morelos-Guzmán,
None;

T. Rodriguez-Reyna,
None;

C. A. Núñez-Alvarez,
None;

J. Vazquez-Lamadrid,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/silent-ischemic-heart-disease-in-patients-with-primary-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology